Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLC590 for postsurgical pain following bunionectomy
NCT03838133Phase 2Completed
- Sponsor
- Taiwan Liposome Company
- Start
- Mar 2019
- Primary completion
- Mar 2020
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TLC590 in Persistent postsurgical pain (PPSP) (6 arms), sponsored by Taiwan Liposome Company. Primary endpoint: Area Under the Curve of Numerical Pain Rating Scale. Started Mar 2019; status: completed.
02
Drugs
TLC590
03
Conditions
Persistent postsurgical pain (PPSP)
Beyond the preview
Go deeper on NCT03838133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03838133.